Abstract: A new class of antibiotics effective against methicillin-resistant Staphylococcus aureus (MRSA) is disclosed. Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penicillin-binding protein (PBP) 2a. This class of antibiotics holds promise in reversing obsolescence of staphylococcal PBPs as important targets for antibiotics. Embodiments of the invention thus provide novel antibacterial compounds that target penicillin-binding proteins and/or other important cellular targets. Methods for inhibiting the growth and/or replication of bacteria using the compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, including drug-resistant strains of Staphylococcus aureus.

Abstract: The invention provides compounds, compositions, and methods to improve or accelerate the healing of a wound. In various embodiments, the methods can include the topical treatment of the wound with the enzyme MMP-8, or the topical treatment of the wound with MMP-8 in combination with administration of an MMP-9 inhibitor, to accelerate the healing of the wound.

Abstract: Herein are described an instrument and a method for using the same. The instrument comprises a fluid channel fluidly connected to at least a first fluid reservoir and a second fluid reservoir; a counter electrode (CE), a reference electrode (RE), and a working electrode (WE); and a potentiostat. The CE, RE, and WE are all disposed within the fluid channel; the potentiostat is isolated from earth ground by at least one isolator and is powered by a floating power supply; and the CE, RE, and WE are each electrically connected to the potentiostat.

Abstract: The disclosure provides a method for diagnosing an active mycobacterium tuberculosis infection by detecting certain RNA biomarkers present in secreted extracellular vesicles isolated from a bodily fluid. The RNA biomarkers in the secreted extracellular vesicles may include a certain mycobacterium RNAs as well as certain host cell RNAs. Also provided is an RNA signature of certain mycobacterium and host cell RNA present in secreted extracellular vesicles indicative of an active tuberculosis infection.

Abstract: A method for determining the likelihood of late ER? breast cancer disease relapse/recurrence is disclosed. Late ER+ breast cancer disease onset and/or recurrence is determined for a period of 5 to 20 years after an initial ER+ breast cancer disease onset in a patient. An ER+ breast cancer patient is assigned a risk score that is compared to a defined threshold value, and identifies the risk score as low risk or high risk for late breast cancer recurrence. A late ER+ breast cancer gene panel of 8 to 15 genes is provided. Subjects having a risk score greater than or equal to that of the threshold value are at a relatively high risk of recurrent disease, and are determined to benefit from aggressive therapeutic intervention, whereas subjects having a risk score less than the threshold value are at a relatively low risk of recurrent disease, and could forego treatment.

Abstract: The viscosity of various ionic liquids (IL), the solvent tetraethylene glycol dimethyl ether (G4), and their mixtures, with or without lithium salts, were measured experimentally. Various compositions were studied spectroscopically. Detailed analysis reveals that G4 preferentially solvates cations, leading to a reduction in the interaction energy between cations and anions and a subsequent enhancement in anion mobility. Diffusivity and ionic conductivity of certain compositions were improved at G4 mole fractions below levels required for a “solvate ionic liquid”. When an IL was combined with low amounts of a 1:1 stoichiometric ratio of G4 and lithium salt, the viscosity of composition remained constant and ion mobility increased.

Abstract: High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient.

Abstract: An Accelerated Progression Relapse Test (APRT) and method is provided for use in the prognosis of a patient having an ER+ breast cancer. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. Four genetic probes are disclosed that target the MKI67, CDC6 and SPAG5 gene and gene products. The ER+ breast cancer patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient group that is more likely to benefit from additional treatment measures.

Abstract: A compound, having the following formula: or resonance form thereof, or salt thereof, or salt of resonance form thereof is provided, wherein E includes an electrophilic site, and wherein R1-R4 and n are defined herein. Compositions and methods including the compound are also provided.

Abstract: Various processor architectures for mixed signal computation exploit the unique characteristics of advanced CMOS technologies, such as fin-based, multi-gate field effect transistors, and/or emerging technologies such as tunnel field effect transistors (TFETs). The example processors disclosed herein are cellular neural network (CNN)-inspired and eliminate the need for voltage controlled current sources (VCCSs), which have previously been utilized to realize feedback and feed-forward templates in CNNs and are the dominant source of power consumption in a CNN array. The example processors replace VCCSs with comparators, which can be efficiently realized with TFETs given their high intrinsic gain. Power efficiencies are in the order of 10,000 giga-operations per second per Watt (GOPS/W), which represents an improvement of more than ten times over state-of-the-art architectures seeking to accomplish similar information processing tasks.

Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.

Abstract: Embodiments herein provide methods of purifying monoclonal and polyclonal anti-bodies (e.g., immunoglobulins) from biological fluids, such as cell lysates, cell supernatant and ascites fluids, using small molecule affinity chromatography. Various embodiments disclose a class of small molecules that selectively bind a nucleotide binding site that is inherent to all immunoglobulins, and in various embodiments, methods are disclosed that use one of these small molecules as a capture molecule in small molecule affinity chromatography. In some embodiments, the small molecule may be an indole, and in particular embodiments, the small molecule may be indole-3-butyric acid.

Abstract: Methods and systems of quantifying a target material in solution include detection of a size change of a hybridized nanoparticle. In particular, the examples include functionalizing a plurality of nanoparticles to adapt the nanoparticles to hybridize with a species-specific target material, measuring the size of the functionalized nanoparticles to predetermine a standard distribution of non-hybridized nanoparticles, introducing the functionalized nanoparticles in a solution containing species-specific target materials and/or non-target materials, and hybridizing the functionalized nanoparticles with the species-specific target material if present in the solution. The size of the nanoparticles in solution are then measured after hybridization, and the presence or non-presence of the species-specific target material is detected and/or quantified by comparing the measured size of the nanoparticles after hybridization to the standard distribution of non-hybridized nanoparticles.

Abstract: A tunnel field-effect transistor device includes a p-type GaN source layer, an n-type GaN drain layer, and an interlayer interfaced between the source-layer and the drain layer. In one example, the interlayer includes an Indium Nitride (InN) layer. In one example, the interlayer includes a graded Indium gallium nitride layer and an InN layer. In one example, the interlayer may include a graded Indium gallium nitride (InxGa1-xN) layer and an Indium gallium nitride (InGaN) layer. In one example, the tunnel field-effect transistor device includes an in-line configuration. In one example, the tunnel field-effect transistor device includes a side-wall configuration.

Abstract: A quilt packaging system includes a first and second electronic device each comprising a plurality of edge surfaces at least a first edge surface of which comprises one or more interconnect modules disposed thereon. The first edge surface of the second electronic device is positioned contiguous to the first edge surface of the first electronic device, and at least one of the one or more interconnect nodules disposed on the first edge surface of the first electronic device is configured to be in physical contact with at least one of the one or more interconnect nodules disposed on the first edge surface of second electronic device so as to provide an electrical connection between the first and second electronic devices at the first edge surfaces of the first and second electronic device.

Abstract: Embodiments herein provide compounds and methods of making and using such compounds for prevention and treatment of multidrug resistant bacteria. In particular, embodiments are directed to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria.

Abstract: First and second integrated devices each have an optical component and a plurality of interconnect structures disposed one edge thereon. The first edge surface of the second integrated device is positioned contiguous to the first edge surface of the first integrated device. The interconnect structures disposed on the first integrated device are in physical contact with the interconnect structures disposed on the edge surface of the second integrated device so as to provide alignment for conveying at least one signal between the optical components on the first and second integrated devices.

Abstract: The invention provides a series of 5,5-heteroaromatic compounds, syntheses thereof, compositions thereof, and methods of using such compounds and compositions. Various embodiments provide methods of killing and/or inhibiting the growth of M. tuberculosis and/or M. avium, and methods of treating, preventing, and/or ameliorating M. tuberculosis and/or M. avium infections in a subject. In various embodiments, the 5,5-heteroaromatic compound is N-(4-(4-chlorophenoxy)benzyl)-2,6-dimethylimidazo[2,1-b]thiazole-5-carboxamide.

Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.

Abstract: Embodiments herein provide methods of purifying monoclonal and polyclonal antibodies (e.g., immunoglobulins) from biological fluids, such as cell lysates, cell supernatant and ascites fluids, using small molecule affinity chromatography. Various embodiments disclose a class of small molecules that selectively bind a nucleotide binding site that is inherent to all immunoglobulins, and in various embodiments, methods are disclosed that use one of these small molecules as a capture molecule in small molecule affinity chromatography. In some embodiments, the small molecule may be an indole, and in particular embodiments, the small molecule may be indole-3-butyric acid.